The mRNA Flu Shot's Rocky Road to Approval The Centers for Disease Control and Prevention continues to track flu cases, but one issue is clear: the first mRNA flu shot, Moderna's mFlusiva, has sparked questions among patients.
Concerns about efficacy and safety are legitimate, but they're not the only issues at play. A disconnect between the FDA's approval process and the CDC's recommendations lies at the heart of the problem.
The FDA cleared mFlusiva for people 50 and older in August, while the CDC remains silent on whether this vaccine is worth using.